Prihlásiť sa Zaregistrujte sa zadarmo

Hotovosť na akciu spoločnosti Midatech Pharma Plc

Aká je hodnota metriky Hotovosť na akciu spoločnosti Midatech Pharma Plc?

Hodnota metriky Hotovosť na akciu spoločnosti Midatech Pharma Plc je 0.07

Aká je definícia metriky Hotovosť na akciu?

Hotovosť na akciu (Cash per share) je pomer ihneď dostupných peňazí prístupných na výdaj a vydaných akcií spoločnosti.

Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.

When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.

Hotovosť na akciu spoločností v sektore Health Care sektor na LSE v porovnaní so spoločnosťou Midatech Pharma Plc

Čomu sa venuje spoločnosť Midatech Pharma Plc?

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Firmy s metrikou hotovosť na akciu podobnou spoločnosti Midatech Pharma Plc